David Mintz, DO
Advanced Heart Failure and Transplant Cardiology · Manhasset, NYNPI 1902326200
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,431 of the $1,735 with a category attached, or 82.5%. 21 manufacturers reported payments, led by Abbott at 24.5% of the total. 2025 is the largest year on record at $972, more than ten times the $34 reported in 2021. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in NY, where the typical reported total is $5,971.
Across 69 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$425
- Merck$174
- Boehringer Ingelheim$167
- Amgen$156
- Alnylam Pharmaceuticals Inc.$123
- Actelion Pharmaceuticals US, Inc.$117
- plus $573 from 15 others
What the payments were for
- Food & beverage$1,43182%
- Education$30418%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 5 | $425 |
| Merck | 10 | $174 |
| Boehringer Ingelheim | 10 | $167 |
| Amgen | 4 | $156 |
| Alnylam Pharmaceuticals Inc. | 7 | $123 |
| Actelion Pharmaceuticals US, Inc. | 7 | $117 |
| Astellas Pharma US Inc | 1 | $99 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $79 |
| Bridgebio Pharma, Inc. | 3 | $57 |
| Pfizer | 3 | $51 |
| Bayer | 3 | $44 |
| AstraZeneca | 2 | $38 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Cvrx, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $26 |
| Boston Scientific | 1 | $24 |
| Impulse Dynamics (USA) Inc. | 1 | $23 |
| Abiomed | 1 | $20 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| United Therapeutics Corporation | 1 | $16 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,735 in reported general payments places this provider in the 15th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
See all advanced heart failure and transplant cardiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 29 | $26,536 |
| Metoprolol Succinate | 34 | $446 |
| Atorvastatin Calcium | 25 | $159 |
| Spironolactone | 28 | $113 |
| Losartan Potassium | 13 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $51 | $26,53629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 106 advanced heart failure and transplant cardiology providers in New York.
Other advanced heart failure and transplant cardiology in Manhasset
- Samit ShahManhasset$12K
- Sirish VullagantiManhasset$6K
- Johanna ContrerasNew York$534K
- Scott FeitellRochester$422K
- Sean PinneyNew York$305K
- Mathew MaurerNew York$249K
- Gregg LanierHawthorne$239K
- Michelle BloomMineola$166K
- Norbert MoskovitsBrooklyn$159K
- Stephen PanValhalla$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.